Mitochondrial Dysfunction in Diabetic Cardiomyopathy: New Therapeutic Targets
DOI:
https://doi.org/10.63682/jns.v13i1.9153Keywords:
Diabetic cardiomyopathy, Mitochondrial dysfunction, Oxidative stress, ATP production, Respiratory chain complex, Targeted therapyAbstract
Background: To evaluate the effects of a mitochondria-targeted therapeutic intervention on mitochondrial bioenergetics, oxidative stress, and cardiac function in patients with DCM.
Methods: This prospective, comparative study enrolled 71 patients with echocardiographically confirmed DCM between March 2023 and March 2024. Participants were assigned to either standard therapy (n=36) or standard therapy plus a mitochondria-targeted agent (n=35). Baseline and six-month follow-up assessments included echocardiographic parameters, NT-proBNP levels, HbA1c, lipid profile, oxidative stress markers, and mitochondrial function measures in peripheral blood mononuclear cells (ATP production, ROS levels, respiratory chain complex I and IV activity, and mitochondrial DNA copy number).
Results: Compared with the standard therapy group, the intervention group demonstrated significantly higher ATP production (p<0.001), increased complex I (p<0.001) and complex IV activity (p=0.002), and lower ROS levels (p<0.001). LVEF improved modestly (p=0.03), while NT-proBNP levels declined (p=0.01). HbA1c decreased slightly but significantly (p=0.03), and malondialdehyde levels were markedly reduced (p<0.001). No major adverse events were reported.
Conclusion: Mitochondria-targeted therapy improved mitochondrial function, reduced oxidative stress, and enhanced selected cardiac performance indices in DCM patients. These findings support the therapeutic potential of targeting mitochondrial pathways alongside conventional management.
Downloads
Metrics
References
Cong, S., et al., Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets. 2020. 3(2): p. 82.
Gollmer, J., et al., Mitochondrial mechanisms in diabetic cardiomyopathy. 2020. 44(1): p. 33.
Dhar, A., et al., A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy. 2023. 17: p. 17539447231210170.
Bai, J., et al., Novel insights into molecular mechanism of mitochondria in diabetic cardiomyopathy. 2021. 11: p. 609157.
Tao, L.-C., et al., The role of mitochondrial biogenesis dysfunction in diabetic cardiomyopathy. 2022. 30(5): p. 399.
Dabravolski, S.A., et al., The role of mitochondrial abnormalities in diabetic cardiomyopathy. 2022. 23(14): p. 7863.
Wang, M., et al., Endothelial dysfunction and diabetic cardiomyopathy. 2022. 13: p. 851941.
Hsuan, C.-F., et al., Emerging therapy for diabetic cardiomyopathy: from molecular mechanism to clinical practice. 2023. 11(3): p. 662.
Cieluch, A., A. Uruska, and D.J.I.J.o.M.S. Zozulinska-Ziolkiewicz, Can we prevent mitochondrial dysfunction and diabetic cardiomyopathy in type 1 diabetes mellitus? Pathophysiology and treatment options. 2020. 21(8): p. 2852.
Grubić Rotkvić, P., et al., The mystery of diabetic cardiomyopathy: from early concepts and underlying mechanisms to novel therapeutic possibilities. 2021. 22(11): p. 5973.
Yang, J., et al., Mitochondrial dysfunction in cardiovascular diseases: potential targets for treatment. 2022. 10: p. 841523.
Peng, C., et al., Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy: new insights from bioinformatics analysis. 2023. 21(1): p. 66.
Wu, T., et al., SIRT6: A potential therapeutic target for diabetic cardiomyopathy. 2023. 37(8): p. e23099.
Tan, Y., et al., Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. 2020. 17(9): p. 585-607.
Manolis, A.S., et al., Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications. 2021. 41(1): p. 275-313.
Cai, Z., et al., Pyroptosis-related inflammasome pathway: a new therapeutic target for diabetic cardiomyopathy. 2022. 13: p. 842313.
Muñoz-Córdova, F., et al., Novel insights into the pathogenesis of diabetic cardiomyopathy and pharmacological strategies. 2021. 8: p. 707336.
Mengstie, M.A., et al., Molecular and cellular mechanisms in diabetic heart failure: Potential therapeutic targets. 2022. 13: p. 947294.
Huang, Y. and B.J.B. Zhou, Mitochondrial dysfunction in cardiac diseases and therapeutic strategies. 2023. 11(5): p. 1500.
Nakamura, K., et al., Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus. 2022. 23(7): p. 3587.
Cojocaru, K.-A., et al., Mitochondrial dysfunction, oxidative stress, and therapeutic strategies in diabetes, obesity, and cardiovascular disease. 2023. 12(3): p. 658.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
